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Conclusions MV-PCI during the index of primary PCI in 
STEMI patients is associated with a higher mortality rate, 
a higher risk of bleeding complications, but lower risk of 
re-intervention and re-infarction and comparable rates of 
MACE.
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Background
About half of the patients presenting with ST-elevation 
myocardial infarction (STEMI) have multivessel disease. 
Compared with STEMI patients with single-vessel disease, 
STEMI patients with multivessel disease have a worse 
prognosis [1–3].
The current guidelines recommend intervention in the 
infarct-related artery only during primary percutaneous 
coronary intervention (PCI) except in haemodynamically 
unstable patients [4]; this is mainly due to the fact that evi-
dence supporting immediate (preventive) intervention in the 
non-infarct-related artery is a matter of debate.
There are controversial data regarding infarct-related 
artery only revascularisation (IRA-PCI) versus multivessel 
revascularisation (MV-PCI) in STEMI patients with multi-
vessel disease [5–19].
Previously, other meta-analyses assessed MV-PCI versus 
IRA-PCI; however, in those meta-analysis, MV-PCI was 
defined as same stage PCI as well as staged PCI days after 
the primary PCI. Furthermore, the results of the most recent 
trials were not included [20–23].
We performed a meta-analysis comparing outcome in 
MV-PCI versus IRA-PCI during the index of primary PCI 
in STEMI patients with multivessel disease.
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Methods
Literature review
The literature search was performed from Cochrane Library, 
EMBASE and MEDLINE, from January 2014 to Decem-
ber 2014. The terms “ST-elevation myocardial infarction”, 
“coronary angioplasty”, “percutaneous coronary inter-
vention”, “multi-vessel”, “non-culprit”, “culprit coronary 
revascularisation”, “complete revascularisation”, “myocar-
dial infarction” and their variations were used as keywords. 
The search was limited to records in humans and English 
language articles.
Study selection
Two reviewers independently screened all citations for 
eligibility. Both randomised controlled trials (RCTs) and 
cohort studies comparing multivessel versus culprit-only 
PCI in patients with STEMI and multivessel coronary artery 
disease treated with primary PCI were included. Studies 
enrolling patients with other than STEMI or comparing 
alternative revascularisation strategies were excluded. Full-
text citations and abstracts were selected and independently 
screened for eligibility in the meta-analysis. The unpub-
lished Complete Versus culprit-Lesion only PRimary PCI 
Trial (CVLPRIT) was also included because of its impor-
tance for this meta-analysis [20]. Quality of abstracted stud-
ies was assessed using the Cochrane Collaboration’s tool for 
assessing risk of bias [24].
Information on study design, inclusion and exclusion cri-
teria, number of patients and clinical outcome was extracted 
by two investigators. Disagreements were resolved by con-
sensus. Finally, all co-authors had full access to all study 
data and take responsibility for the integrity of the data and 
the accuracy of the data analysis.
Definitions
MV-PCI was defined as PCI of the infarct-related artery 
(IRA) and non-IRA performed during the index primary 
PCI procedure for STEMI. IRA-PCI is defined as the PCI 
of the IRA only during the index primary PCI procedure. 
Major adverse cardiac event (MACE) was defined as the 
composite of death, re-infarction and revascularisation. 
Bleeding included both minor and major bleeding.
Endpoints/data abstraction
The primary clinical endpoint was all-cause mortality. 
Secondary endpoints were re-infarction, revascularisation, 
bleeding and MACE.
Statistical analysis
Continuous data were expressed as mean ± standard devia-
tion and dichotomous data as absolute values and percent-
ages. Mantel–Haenszel model was used to construct random 
effects summary odds ratios (ORs) and risk differences. All 
analyses were performed using Review Manager (RevMan, 
Version 5.0, The Nordic Cochrane Centre, The Cochrane 
Collaboration 2008) and SAS 9.3, (SAS Institute, Cary, 
NC). p-Value < 0.05 was considered statistically significant.
Results
The search yielded 15 studies [5–19]: 5 RCTs and 10 
cohort studies. The characteristics of the included studies 
are shown in Table 1. A total of 35,975 patients comprised 
the study population including 1134 (3.2 %) patients from 
RCTs. MV-PCI was performed in 5109 (12.2 %) patients, 
and 30,939 (85.8 %) patients underwent IRA-PCI.
Patient characteristics
Table 2 shows the baseline characteristics of the study pop-
ulation. The vast majority of the studies excluded patients 
with cardiogenic shock and in two trials cardiogenic shock 
was not reported.
Clinical outcomes
The primary endpoint, all-cause mortality, was significantly 
higher in the MV-PCI (8.5 %) compared with the IRA-PCI 
(5.4 %) group (OR 1.57, 95 % CI 1.40–1.76, p < 0.001) 
(Fig. 1). However, analysis limited to the five RCTs only 
showed no significant difference in mortality rate between 
MV-PCI and IRA-PCI (OR 0.74, 95 % CI 0.43–1.26, 
p = 0.27).
Secondary endpoints
Rates of re-infarction (OR 0.54, 95 % CI 0.34–0.88, 
p = 0.01) and revascularisation (OR 0.67, 95 % CI 0.48–
0.93, p = 0.002) were lower in the MV-PCI group. This was 
found for both randomised and cohort trials (Fig. 2a and b).
Bleeding complications (major and minor) occurred 
more often in the MV-PCI group: 6.2 versus 5.1 %, (OR 
1.24, 95 % CI 1.08–1.42, p = 0.002) and this was mainly 
found in the cohort studies (Fig. 3).
MACE was comparable between the two groups: 19 
versus 19.5 % (OR 0.94, 95 % CI 0.74–1.19, p = 0.59). In 
the RCT trials, MACE was significantly lower in patients 
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ies, mortality and bleeding complications were significantly 
higher in the MV-PCI group; however, these were not sig-
nificantly different in the randomised trials between the 
MV-PCI group versus IRA-PCI group (Figs. 1 and 4).
Approximately 40–65 % of patients with STEMI have 
multivessel disease with increased risk of morbidity and 
mortality compared with single-vessel disease [1–3]. The 
underlying mechanism for this adverse prognosis may be 
plaque instability, impaired myocardial perfusion and con-
tractility, arrhythmia and death.
Discussion
In this large scale meta-analysis, we found that PCI of the 
IRA and non-IRA performed during the index primary PCI 
procedure for STEMI, compared with IRA-only PCI, is 
associated with a higher mortality rate and more bleeding 
complications, but less re-infarction and revascularisation. 
Rates of MACE were comparable between the two groups. 
However, there was a clear difference in outcome between 
the randomised trials and cohort studies. In the cohort stud-
Study Design Subjects Inclusion criteria Exclusion criteria Primary endpoint Mean length 
follow-up
Cavender Cohort study 28,936 STEMI with CAD of > 1 major 
artery
LM, staged PCI (multiple PCIs 





Corpus Cohort study 532 STEMI with > 70 % stenosis of ≥ 2 
arteries
PCI of graft or after angio-
plasty, LM, planned staged 
revascularisation
MACE 12 months
Di Mario Randomised 69 STEMI with MVD and 1–3 
lesions in non-culprit artery tech-
nically amenable to revascularisa-
tion by stent
Lesion in vein and arterial grafts, 










Hannan Cohort study 1006 STEMI with MVD LM disease, prior thrombolysis, 





Khattab Cohort study 73 STEMI with > 70 % stenosis of 
≥ 2 coronary arteries or major 
branches
Non-IRA diameter < 2.5 mm, 
LM disease, previous MI
MACE 12 months
Kornowski Cohort study 668 STEMI with MVD TIMI flow < 3 in non-IRA MACE 12 months
Ochala Randomised 92 STEMI with > 70 % stenosis of ≥ 2 
coronary arteries, successful PCI 
of IRA
Cardiogenic shock, LM disease, 
pervious CABG, renal insuffi-




Politi Randomised 214 STEMI with > 70 % stenosis of 
≥ 2 coronary arteries or major 
branches
Cardiogenic shock, LM > 50 %, 
pervious CABG, severe valvular 
heart disease or unsuccessful 
procedure
MACE 30 months
Qarawani Cohort study 120 STEMI with > 70 % multivessel 
narrowing
Cardiogenic shock, LM disease Clinical outcome 12 months
Roe Cohort study 129 STEMI with ≥ 50 % stenosis of ≥ 1 
non-culprit artery in addition to 
culprit IRA






Toma Cohort study 2201 STEMI with > 70 % stenosis of > 1 
major epicardial artery and/or a 
non-IRA requiring intervention
PCI on LM, second intervention 




Varani Cohort study 399 STEMI with > 70 % stenosis of 
≥ 2 epicardial arteries or major 
branches
Occlusion after prior angioplas-
ty, cardiogenic shock, pulmonary 
oedema
Death and repeat 
revascularisation
1 month
Wald Randomised 465 STEMI with ≥ 50 % stenosis of ≥ 1 
non-IRA in addition to IRA
Cardiogenic shock, LM > 50 %, 
pervious CABG
MACE 23 months
Gershlick Randomised 294 STEMI with > 70 % stenosis of 
≥ 2 epicardial arteries or major 
branches (> 2 mm)
Cardiogenic shock, previous MI, 
pervious CABG, chronic kidney 
disease, CTO
MACE 12 months
CABG coronary artery bypass graft, CAD coronary artery disease, CHF congestive heart failure, CTO chronic total occlusion, IRA infarct-
related artery, LM left main artery, LVEF left ventricular ejection fraction, MACE major adverse cardiac events, MI myocardial infarction, MVD 
multivessel disease, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction, TIMI thrombolysis in myocardial 
infarction
Table 1 Study characteristics
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Finally, patients and clinicians may be more comfortable 
with complete revascularisation rather than medical therapy 
for angiographically significant residual coronary stenosis, 
especially if they are associated with a large territory of 
myocardial jeopardy [27–30].
However, multivessel PCI also has disadvantages. In the 
acute phase of STEMI, intervention of a non-culprit lesion 
may result in unnecessary haemodynamic compromise dur-
The potential advantages of MV-PCI during the index 
primary PCI may prevent recurrent ischaemia and infarc-
tion by decreasing total ischaemia and improvement in 
myocardial function [25, 26]. Plaque instability may not 
be limited to the IRA but may involve other territories in 
the coronary vasculature. Moreover, complete revasculari-
sation has been associated with improved long-term clini-
cal outcome in patients with stable coronary artery disease. 
Table 2 Baseline characteristics
Study Age Male (%) Diabetes (%) Anterior MI (%) Cardiogenic shock (%)
MV-PCI IRA-PCI MV-PCI IRA-PCI MV-PCI IRA-PCI MV-PCI IRA-PCI MV-PCI IRA-PCI
Cavender 60 62 71.5 72.1 24.7 23.4 NR NR 13.8 10.3
Corpus 64 63 70 70 19 17 NR NR 3.3 3.4
Di Mario 64 65 88.2 84.6 11.5 41.5 51.9 58.8 Excluded Excluded




Hannan NR NR 77.5 75.5 23.7 21.4 NR NR Excluded Excluded
Khattab 69 65 75 78 7 16 57 54 3.6 4.4




Ochala 65 67 72.9 75 31 34 45.8 45.4 Excluded Excluded
Politi 65 65 76.9 77.8 14 21 48 43 Excluded Excluded
Qarawani 66 67 62 61 13 16 51 52 Excluded Excluded
Roe 64 63 77.2 65.8 37 29 46 41 28 28
Toma 64 64 74 73 12 20 56 48 3 3
Varani 69 67 68.7 67 NR NR 49 34 Excluded Excluded
Wald 62 62 76 81 35 48 29 39 Excluded Excluded
Gershlick 65 65 85 77 12.9 14.3 36 35.6 Excluded Excluded
IRA-PCI infarct-related artery only revascularisation, MI myocardial infarction, MV-PCI multivessel revascularisation, NR not reported
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important concern is poor assessment of lesion severity in 
non-culprit artery [22]. Hanratty et al. [30] demonstrated 
that 21 % of the non-culprit lesions are overestimated at 
time of AMI, and this may affect unnecessary revascularisa-
tion and inappropriate decision making. The severity of the 
ing PCI with balloon inflations or vessel-related complica-
tions (dissection, no-reflow) at a time when the patient has 
regional myocardial compromise. Given the extended dura-
tion of the intervention, increased contrast load and addi-
tional adverse peri-procedural outcomes may occur. Another 
Fig. 2 a Forest plot of re-infarc-
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reserve (FFR). FFR of the non-IRA was performed 7.5 days 
after primary PCI, and they found functional stenosis sever-
ity of non-culprit lesions is frequently overestimated and 
invasive strategy for non-culprit lesions did not lead to an 
increase in ejection fraction or a reduction in MACE [31].
non-culprit artery was judged visually and PCI of the non-
IRA was not ischaemia guided in any of the studies included 
in this meta-analysis.
There is only one randomised study in which revascu-
larisations on the non-IRA was guided by fractional flow 
Fig. 4 Forest plot of major 
adverse cardiac events (death, 
re-infarction and re-percutaneous 
coronary intervention)
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Conclusion
Multivessel PCI during the index of primary PCI in STEMI 
patients is associated with a higher mortality and more 
bleeding, but a lower risk of re-intervention and re-infarc-
tion. Additional large-scale randomised trials are needed to 
guide the therapy and the timing for these patient subsets.
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